全文获取类型
收费全文 | 388篇 |
免费 | 26篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 10篇 |
基础医学 | 18篇 |
口腔科学 | 1篇 |
临床医学 | 17篇 |
内科学 | 35篇 |
神经病学 | 7篇 |
特种医学 | 2篇 |
外科学 | 10篇 |
综合类 | 40篇 |
预防医学 | 5篇 |
眼科学 | 4篇 |
药学 | 65篇 |
中国医学 | 2篇 |
肿瘤学 | 199篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 8篇 |
2018年 | 5篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 12篇 |
2014年 | 21篇 |
2013年 | 24篇 |
2012年 | 21篇 |
2011年 | 20篇 |
2010年 | 10篇 |
2009年 | 11篇 |
2008年 | 18篇 |
2007年 | 24篇 |
2006年 | 23篇 |
2005年 | 21篇 |
2004年 | 17篇 |
2003年 | 7篇 |
2002年 | 17篇 |
2001年 | 11篇 |
2000年 | 17篇 |
1999年 | 19篇 |
1998年 | 12篇 |
1997年 | 15篇 |
1996年 | 20篇 |
1995年 | 12篇 |
1994年 | 11篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1984年 | 2篇 |
排序方式: 共有424条查询结果,搜索用时 15 毫秒
11.
《Biology of blood and marrow transplantation》2014,20(1):73-79
We conducted a multicenter retrospective study to compare the efficacy and toxicity of various chemomobilization regimens: high-dose (HD) cyclophosphamide, HD etoposide (VP-16), and platinum-based chemotherapies. We reviewed the experiences of 10 institutions with 103 non-Hodgkin lymphoma patients who had previously only been treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy. The mobilization yields for each regimen were analyzed. HD VP-16 mobilized a significantly higher median number of CD34+ cells (16.22 × 106 cells/kg) than HD cyclophosphamide (4.44 × 106 cells/kg) or platinum-based chemotherapies (6.08 × 106 cells/kg, P < .001). The rate of successful mobilization (CD34+ cell count ≥5.0 × 106 cells/kg) was also significantly higher for HD VP-16 (86%) than for HD cyclophosphamide (45%) or platinum-based chemotherapies (61%, P = .004). The successful mobilization rate on day 1 of 72% for HD VP-16 was significantly higher than the rates for HD cyclophosphamide (13%) and platinum-based chemotherapies (26%, P < .001). In multivariate analysis, HD VP-16 was a significant predictor of successful mobilization (P = .014; odds ratio, 5.25; 95% confidence interval, 1.40 to 19.63). Neutropenic fever occurred in 67% of patients treated with HD VP-16. The incidence was similar for HD cyclophosphamide (58%, P = .454) but was significantly lower for platinum-based chemotherapies (12%, P < .001). However, fatal (grade ≥ 4) infection and treatment-related mortality were not observed in this study. In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma. 相似文献
12.
BACKGROUND Combined small cell lung cancer(C-SCLC) is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis. Currently, there are limited studies on C-SCLC, and there is no uniform standard treatment, especially for extensive C-SCLC, which still faces great challenges. In recent years, the development and progress of immunotherapy have provided more possibilities for the treatment of C-SCLC. We used immunotherapy c... 相似文献
13.
14.
15.
鬼臼乙叉甙静脉5天用药治疗老年人小细胞肺癌临床分析(附30例报告) 总被引:1,自引:0,他引:1
目的 观察单独应用鬼臼乙叉甙(VP-16)静脉给药5d治疗老年人小细胞肺癌的临床效果及其毒性反应。方法30例老年人小细胞肺癌患者,采用VP-16单药静脉化疗。结果 完全缓解9例(30.0%)、部分缓解15例(50.0%)、微效4例(13.3%)、稳定1例(3.3%)、进展1例(3.3%),有效率80.0%。全组中位生存期15个月,其中有效者中位生存时间20.5个月,无效者中位生存时间8个月,两者比较有显著性差异(P=0.013)。1、2、3年生存率分别为66.7%、40.0%、20.0%。毒性反应较轻,患者均能耐受,以轻度骨髓抑制和肝功能受损为主,恶心、呕吐少见。结论 静脉5d单独用VP-16治疗老年人小细胞肺癌的疗效可靠、使用方便、毒副反应轻。 相似文献
16.
Heeseok Kang Tae-Joong Kim Chel Hun Choi Jeong-Won Lee Je-Ho Lee Duk-Soo Bae Byoung-Gie Kim 《Journal of Korean medical science》2009,24(5):945-950
The aim of this trial was to investigate the efficacy and toxicity of combination chemotherapy with etoposide and ifosfamide (ETI) in the management of heavily pretreated recurrent or persistent epithelial ovarian cancer (EOC). Patients with recurrent or persistent EOC who had measurable disease and at least two prior chemotherapy participating in this phase II trial were to receive etoposide at a dose of 100 mg/m2/day intravenously (IV) on days 1 to 3 in combination with ifosfamide 1 g/m2/day IV on days 1 to 5, every 21 days. Thirty-seven patients were treated; about 78% had previously received more than two separate regimens. The response rate (RR) was 18.9% and median duration of response was 7 months (range, 1-15). Treatment free interval prior to ETI (TFI) has significant correlation with RR rate (P=0.034). Patients (n=6) with TFI ≥6 months had 50% of RR, while patients (n=31) with TFI <6 months had 12.9%. Median survival was 9 months at a median follow-up of 9.2 months. Grade 3 or 4 toxicities included neutropenia in 20.1% of the 139 cycles of ETI, anemia in 7.2% and thrombocytopenia in 8.6%. The ETI produces relatively low toxicity and modest activity in heavily pretreated recurrent or persistent EOC. This is significant in patients with TFI ≥6 months. 相似文献
17.
Bente Holm Peter Buhl Jensen Maxwell Sehested Heine Høi Hansen 《Cancer chemotherapy and pharmacology》1994,34(6):503-508
A number of clinically important drugs such as the epipodophyllotoxins etoposide (VP-16) and teniposide (VM-26), the anthracyclines daunorubicin and doxorubicin (Adriamycin), and the aminoacridine amsacrine exert their cytotoxic action by stabilizing the cleavable complex formed between DNA and the nuclear enzyme topoisomerase II. We have previously demonstrated in several in vitro assays that the anthracycline aclarubicin (aclacinomycin A) inhibits cleavable-complex formation and thus antagonizes the action of drugs such as VP-16 and daunorubicin. The present study was performed to validate these in vitro data in an in vivo model. At nontoxic doses of 6 and 9 mg/kg, aclarubicin yielded a marked increase in the survival of non-tumor-bearing mice given high doses of VP-16 (80–90 mg/kg) in six separate experiments. In therapy experiments on mice inoculated with Ehrlich ascites tumor cells, aclarubicin given at 6 mg/kg roughly halved the increase in median life span induced by VP-16 at doses ranging from 22 to 33 mg/kg. An attempt to determine a more favorable combination of VP-16 and aclarubicin by increasing VP-16 doses failed, as the two drugs were always less effective than VP-16 alone. The way in which VP-16-induced DNA strand breaks lead to cell death remains unknown. However, VP-16 has been reported to cause apoptosis (programmed cell death) in several cell lines. To ascertain whether the protection given by aclarubicin could have a disruptive effect on the apoptotic process, we used the small intestine as an in vivo model. Whereas VP-16-induced apoptosis in crypt stem cells was detectable at a dose as low as 1.25 mg/kg, aclarubicin given at up to 20 mg/kg did not cause apoptosis. Indeed, aclarubicin caused a statistically significant reduction in the number of cells rendered apoptotic by VP-16. The present study thus confirms the previous in vitro experiments and indicates the value of including an in vivo model in a preclinical evaluation of drug combinations.This work was supported by the Danish Cancer Society 相似文献
18.
Hideki Kondo Fumihiko Kanzawa Kazuto Nishio Shiro Saito Nagahiro Saijo 《Cancer science》1994,85(10):1050-1056
The effects of cisplatin (CDDP) and etoposide (ETP) in combination were evaluated in vitro and in vivo using small cell lung cancer cell lines. The combination effects in vitro were investigated using isohologram analysis. Used together, CDDF and ETP showed a synergistic effect against cell growth on only 1 cell line (SBC-3), additive effects on 6 (SBC-2, SBC-5, Lul30, Lul34AH, Lul35T and H69) and an antagonistic effect on 1 (SBC-1). In the in vivo experiment, nude mice were inoculated with SBC-1, SBC-3 and SBC-5 cells. Two or 5 mgAg CDDP and 10 or 30 mgAg ETP were administered intraperitoneally alone and simultaneously in combination to nude mice. The in vivo effects of the combination were determined by comparing the observed growth ratio in mice treated with the combination with the expected value of this ratio calculated based on the assumption that the effects of the drugs were simply additive. According to this definition, synergistic effects were observed against all 3 tumors. Thus, the in vivo and in vitro effects differed. The toxicity of the combination therapy, which was analyzed by estimating the body weight change of mice, was no higher than that of CDDP or ETP alone. These results suggest that the excellent clinical effects of CDDP and ETP combination therapy may he attributable not to drug interaction at the cellular level hut to the feasibility of combined use of them at full doses without overlapping side effects. 相似文献
19.
Bo Liu Helena M. Earl Christopher J. Poole Janet Dunn David J. Kerr 《Cancer chemotherapy and pharmacology》1995,36(6):506-512
The protein binding of etoposide was studied in vivo in 36 cancer patients receiving etoposide therapy. Free etoposide was separated from plasma using an ultrafiltration method and the etoposide concentrations (free and total) were measured by high-performance liquid chromatography (HPLC). Considerable interpatient variation in the protein binding of etoposide was observed. The protein binding of etoposide varied from 80% to 97% (mean, 93%). Univariate analysis showed a significant inverse correlation between the free fraction of etoposide and serum albumin (r=–0.74), daily dose (r=–0.37) and age (r=–0.34). Multivariate analysis demonstrated that serum albumin and age were independent predictors of the etoposide free fraction. Serum bilirubin showed no correlation with etoposide protein binding. There is wide variation in etoposide protein binding in cancer patients, which is mostly dependent on serum albumin concentration. 相似文献
20.
Yuichi Ando Hironobu Minami Shuzo Sakai K. Shimokata 《Cancer chemotherapy and pharmacology》1996,37(6):616-618
The prolonged continuous infusion of low-dose etoposide is a new approach to treating cancer. Whether or not a circadian
variation in the plasma levels of etoposide existed was investigated in nine patients with non-small-cell lung cancer. Etoposide
was infused for 14 days and blood samples were obtained every 4 h for 1 day. There was no significant circadian variation,
and the observed small within-day variations seemed to lack clinical significance.
Received: 24 March 1995 / Accepted: 2 August 1995 相似文献